In glioma, mild to moderate depressive symptoms may only rarely be due to tumor-associated structural or functional disruption of neuronal emotional networks. Improved methodological reporting would help clinicians better evaluate future studies, and facilitate improved evidence-based care of depressed glioma patients.
Depression is a well-recognized complication of cerebral glioma (1-3), but it can be challenging to study (4, 5) . Primary symptoms of depression are difficult to distinguish from the consequences of tumor or treatment (1, 3, 6) . However, true clinical depression can and does develop following a decline in health (7, 8) and is of great practical relevance to patients. Among all cancer patients, those diagnosed with glioma have the highest risk of clinically significant psychiatric complications in the period surrounding their diagnosis (9, 10) . Poor mental health has potentially important consequences. Depression may adversely affect quality of life (1) (2) (3) 11) and is an independent predictor of mortality in patients with systemic cancer arising beyond the central nervous system (12) .
Many things remain unknown about depression in glioma. Depression in these patients has been conceptualized as a biological disease (3, 4, (13) (14) (15) (16) , a psychological reaction to the losses associated with a diagnosis of brain cancer (7, (17) (18) (19) (20) , or both (1, 2, 5, (21) (22) (23) . Estimates of the frequency of depression in patients with glioma range from 0% (5) to 93% (21) . There are conflicting observational data from glioma patients regarding associations between depression and sex (13, 15) , functional status (13, 21) , past psychiatric history (4, 14) , tumor size (15, 24) , tumor laterality (24, 25) , tumor grade (5, 26) , the affected lobe of the brain (14, 21) , steroid treatment (1, 25) , radiotherapy treatment (1, 27) , chemotherapy treatment (18, 28) , medical complication rates (13, 29) , and survival (13, 30) . Potential sources of these discrepancies include differences in the study methods (1, 3, 19, 21) , study populations (31, 32) , sampling time points (15, 31, 32) , and the quality of reporting (33) .
These uncertainties reinforce the need to study depression in patients with glioma. A better understanding of its diagnosis, frequency, and associated clinical characteristics may help focus future research priorities and support evidence-based patient care. Correspondence to: Alasdair G. Rooney, MBChB, Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, UK, EH4 2XU (e-mail: a.rooney@nhs.net)
Background
Depression is a common and important complication of primary cerebral glioma. However, observational studies of this relationship have not been systematically reviewed.
Methods
We searched MEDLINE, EMBASE, and PsycINFO for all English-language cross-sectional, case-control, and cohort studies of depression in adults with primary glioma published between January 1, 1980, and September 16, 2009 . We identified 42 eligible studies that recruited 4089 individual glioma patients. We conducted a narrative review of these studies regarding the heterogeneity in diagnostic methods, the frequency of depression and its clinical associations, and the quality of study reporting.
Results
Most studies of depression in adults with glioma were small, cross-sectional, or retrospective. Depression was most often measured using the Hospital Anxiety and Depression Scale (HADS; n = 10 studies). The Beck Depression Inventory, another frequently used screening instrument, returned a higher frequency of depression (median = 39%, range = 38%-42%) than the Hospital Anxiety and Depression Scale (median = 16%, range = 0%-21%). At clinical interview, the median frequency of depression in glioma was 15% (range = 6%-28%). Depression was consistently associated with reduced physical function, cognitive impairment, and reduced quality of life. It may be associated with reduced survival, although evidence for this association was modest. There was an absence of clear associations between depression and many tumor-related variables. Few observational studies examined the treatment of depression in glioma patients. Multivariable analyses were rare, and study reporting was of variable quality.
Previous reviews of this topic were not conducted systematically; in addition, they included data on conditions that are fundamentally different from glioma, such as meningiomas and pituitary tumors (1, 2, 27, 34) . We conducted a systematic literature search and review of observational studies of depression in adults diagnosed with glioma. We specifically examined 1) the extent of heterogeneity in diagnostic methods, 2) the reported frequency of depression, 3) clinical factors associated with depression in glioma patients, and 4) the quality of study reporting.
Methods
We conducted a search of the published English-language literature in the MEDLINE, EMBASE, and PsycINFO databases from January 1, 1980, to September 16, 2009 , using the search terms shown in Box 1. We included all cohort, case-control, and cross-sectional studies that presented original data on any aspect of depression in patients with a supratentorial glioma who were older than 18 years at diagnosis. We allowed any method of diagnosing glioma and all methods of diagnosing depression, except depression subscales of general quality-of-life assessment instruments. We excluded quality-of-life subscale data because quality-of-life scales measure a wider construct than depressionspecific rating scales and are not designed to identify clinical depression.
We also excluded case reports, clinical trials of medications, and studies with fewer than 10 glioma patients (because with so few patients it was difficult to differentiate between a case series and a very small cohort). To keep this review as specific as possible, we excluded any study that included tumors with cell origins that differ from that of glioma (eg, studies that enrolled patients with glioma, meningioma, and pituitary tumors) unless more than 50% of the sample had glioma, the glioma data were presented separately, or histological tumor type was specifically shown to have no association with depression in that study. We excluded all studies published before January 1, 1980 based on the assumption that the lack of widespread computerized tomography scanning before 1980 would weaken their reliability [the older literature has been reviewed elsewhere (27) ].
One author (A. G. Rooney) performed the systematic search, screened all titles and abstracts, obtained all potentially eligible papers in full text, and checked their eligibility. This author also screened the reference lists of all eligible studies. All titles identified via references were obtained in full text and checked for eligibility.
A data extraction form was designed by consensus among all authors. One author (A. G. Rooney) extracted the data from all eligible studies, entered them into a Microsoft Excel database, and synthesized the results in a narrative review in consultation with the other authors. Data were recorded for high-grade glioma and low-grade glioma separately if they were clearly presented in the original study. Where possible, the World Health Organization (WHO) grading system (35) was used to categorize gliomas, based on their histological features of malignancy, into low grade or high grade. We summarized clinical associations grouped into four broad categories of variables, related to the patient, the tumor, the treatment, and the outcome. We used the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement (33) as a guide for evaluating the quality of reporting of the primary studies.
CONT E X T A N D C A V E A T S

Prior knowledge
Depression is a common and important complication of primary cerebral glioma.
Study design
A systematic review of 42 observational studies of depression in adults with primary glioma published between January 1, 1980, and September 16, 2009 , focusing on the heterogeneity in diagnostic methods, the frequency of depression and its clinical associations, and the quality of study reporting.
Contribution
The Hospital Anxiety and Depression Scale appeared to be a better choice as an initial screening instrument for depression compared with the Beck Depression Inventory, which appeared to magnify depression frequency compared with clinical interview. Clinically diagnosable depression occurred in roughly 15% of glioma patients. Depression was consistently associated with functional impairment, cognitive dysfunction, and reduced quality of life. Evidence for other associations was contradictory, absent or methodologically flawed. The quality of study reporting was variable, which limited comparability and generalizability of the findings.
Implications
Improved methodological reporting would help clinicians better evaluate future studies and facilitate improved, evidence-based care of depressed glioma patients.
Limitations
The review excluded non-English-language papers and studies that enrolled patients younger than 18 years, focused solely on quality of life, had very few glioma patients, and/or in which the total number of patients with glioma was not stated. Included studies were generally biased toward younger patients than those found in actual clinical samples. Additional studies were identified by reference scanning (n = 3) and author knowledge (n = 4) for a total of 42 eligible studies.
From the Editors
Overview of Study Designs and Aims
The designs and aims of all included studies are listed in Table 1 . Most studies were cross-sectional and focused on outcomes other than depression. Depression was an outcome in 10 prospective cohort studies (4, 21, 25, 31, 36, 38, 40, 41, 43, 57) , three of which (4, 40, 41) were drawn from a single dataset. All cohort studies had a baseline measurement of depression at or around the time of the primary surgery. The most common research questions among the 19 studies that focused on depression were about its frequency and clinical associations. Few studies examined depression with respect to etiology, methods of diagnosis, phenomenology, clinical course, and naturalistic treatment. Ten studies (9, 15, 16, 23, 28, 31, 46, 49, 53, 57) included a control group.
Participants
The 42 eligible studies reported data on a total of 4683 patients (median sample size = 51 patients, range = 10-1052 patients). After adjusting for overlap between studies published from the same dataset, there were 4089 unique glioma patients. Among studies that specified glioma grade, 3308 unique patients had high-grade glioma and 355 patients had low-grade glioma (see Table 2 for full details of how these numbers were derived). These proportions of patients with high-grade glioma (90.3%) and low-grade glioma (9.7%) are reasonably reflective of the proportions of high-grade glioma (85%) and low-grade glioma (15%) previously reported in clinical populations (58) . There was, however, a slight bias toward the inclusion of high-grade glioma patients. Among included studies, slightly more of the patients were men (median = 56%, range = 40%-71%). This slight male bias is consistent with the demographic characteristics of glioma (59) . The median age of subjects at study entry was 46 years (range = 26-61 years). The incidence of glioma increases with increasing age (59) ; therefore, eligible studies may have been biased toward including younger patients. Most studies did not report data on ethnicity, marital † Primary: the main hypothesis of the study regards depression, either as a dependent or independent variable. Secondary: depression was measured as part of a wider battery of tests or was explicitly stated to be a secondary outcome. ‡ Papers from the same dataset. § Papers from the same dataset.
status, and employment status. In those that did, most participants were white (median = 93%, range = 63%-100%) and married (median = 73%, range = 67%-78%), whereas their employment status varied considerably (median employed = 45%, range = <25%-100%).
Heterogeneity in Diagnostic Methods
Twenty-five distinct methods were used to diagnose depression in the 42 eligible studies. General diagnostic approaches included a variety of continuous and dichotomized patient-rated scales (4, 5, 15, 16, (18) (19) (20) (21) (22) (23) (24) (25) (26) 28, 30, 31, (36) (37) (38) (39) (40) (41) 43, 46, 47, 51, 53, 54, 57) , hospital discharge records (9), physician report (13, 21, 29, 42, 52) , caregiver report (48) , and patient interview or report (21, 45) . Only one study (14) diagnosed depression on the basis of a structured clinical interview, and three studies used unstructured clinical interviews (5,44,49) ( Table 3) . Most methods of diagnosing depression relied on patient selfreport. The single most commonly used instrument for measuring depressive symptomatology was the Hospital Anxiety and Depression Scale (HADS) (60) , which was used in 10 studies (5, 19, 20, 22, 31, 38, 46, 47, 54, 57) . Eight distinct clinician-based methods of diagnosing depression were applied in nine studies (5, 13, 14, 21, 29, 42, 44, 49, 52) (Table 3 ). By contrast, there was far less variability in the methods used to diagnose glioma; in most studies, a glioma diagnosis was based on histopathology (9, 10, 13, 14, 16, (18) (19) (20) (21) 23, 24, (28) (29) (30) 36, 37, 44, 45, 47, 49, 51, 52, 55, 56) and less often on radiology (4,25,31,38-41,57) or patient selfreport (22, 54) .
Frequency of Depression
Depression was reported as a categorical variable (eg, as "present" or "absent" according to either a rating scale score or clinical judgment), a continuous variable (eg, a scale score presented without reference to a diagnostic threshold), or a combination of both. Patient-rated measures usually returned a higher prevalence of depression than clinician-rated measures (median prevalence [range] for patient-rated and clinician-rated measures: 27% [0%-93%] and 15% [5%-28%], respectively). Studies that used the same diagnostic method generally reported similar mean scores for the severity of depression. For example, in the 10 studies (5, 19, 20, 22, 31, 38, 46, 47, 54, 57) that used the HADS depression subscale (which ranges from 0 [no symptoms of depression] to 21 [the highest possible depression score]), the mean score (SD) ranged from 3.15 (2.3) to 6.2 (not given) ( Table 3) . Because a HADS threshold score of 11 or higher is often used to represent clinically significant depression (60), the average severity of depressive symptoms across the whole sample was low in all the studies that provided mean score data.
Scores from depression rating scales including the HADS, the Beck Depression Inventory (BDI), the Patient Health Questionnaire-9 (PHQ-9), and the Zung Self-Rating Depression Scale (ZSDS) can be dichotomized to indicate either the likely presence or the likely absence of depression. However, because they each measure slightly different symptoms, different scales may differ in the frequency with which they identify similar patients as depressed . This appeared to be the case in patients with glioma. The BDI identified depression in 38%-42% of glioma Table 2 . Demographic characteristics of subjects in the included studies* (21) was counted toward the total of unique glioma patients given in the text; data from Chang et al. (52) were excluded. § Only the median age of subjects at study entry was given in these papers. ║ Papers from the same dataset. Only data from Mainio et al. (41) was counted toward the total of unique glioma patients given in the text; data from Mainio et al. (4, 39, 40) were excluded. ║ In this study, the raw POMS score was transformed to a scale of 0 to 100 and depression was considered clinically significant in patients whose transformed score was ≤50. ¶ These studies are publications from the same dataset.
# In this study, mean BDI score was given separately for patients with right-sided and those with left-sided tumors. The mean presented in this table is the average of those two means.
patients screened (median = 39%) (18, 37, 39) , a frequency similar to that returned by the PHQ-9, which found a depression prevalence of 41% in the only study to use this instrument (26) . By contrast, the HADS (median depression prevalence = 16%, ranges 0%-21%) (5, 20, 31, 38, 54) and ZSDS returned much lower frequency estimates (8% and 10%) (25, 28) . Data from clinical interviews, which are methodologically more robust than rating scales, recorded a depression prevalence ranging from 6% to 28% (median = 15%) (5, 14, 44, 49) . The BDI and PHQ-9 scales therefore appeared to overestimate the frequency of depression in glioma compared with studies that used clinical interview methodology. The diagnostic methods, sampling time points, and depression frequency outcomes are presented in Table 3 .
Clinical Variables Associated with Depression
Associations between most clinical variables and depression, when studied, were inconsistent across studies. Statistical analyses were usually univariate. Associations that were examined in studies in which depression was a primary outcome are presented in Table 4 . A summary of the current evidence for these variables is presented in Table 5 .
Patient-Related Factors
Although some studies found an association between female sex and depressive symptoms (15, 16, 26, 31, 36) , most did not (5, 13, 18, 19, 21, 25, 30, 40, 42, 53) . The two studies in which depression was diagnosed by clinical interview found no association between patient sex and depression (21, 42) . Studies of patients with high-grade glioma consistently found no association between sex and depression, regardless of whether depression was diagnosed perioperatively (13, 19, 21) , before chemotherapy (30), or after recurrence (53) . However, two studies of patients with lowgrade glioma (16, 36) reported statistically significant univariate associations between patient sex and depression. Therefore, it remains possible that sex may play a larger role mediating symptoms of depression in patients with low-grade glioma than in those with high-grade glioma. Overall, female sex was not a clear risk factor for depression in glioma. Considering that depression in the general population is generally accepted to be more common in women, the apparent absence of a sex bias suggests a relatively increased risk of depression for male glioma patients (42) . Many studies examined the association between age (either at study entry or at the diagnosis of glioma) and depression (4, 5, (13) (14) (15) 18, 19, 21, 23, 26, 30) . Age at these time points did not appear to be associated with depression either in glioma patients as an overall group (4, 5, 14, 15, 18, 26) or in the subgroup of patients with highgrade glioma (13, 19, 21, 23, 30) . There was also no association between age and depression regardless of whether depression was measured using a scale (4, 5, 15, 18, 19, 26) or diagnosed on the basis of clinical judgment (13, 14, 21) . There was no evidence specific for patients with low-grade glioma.
Six studies examined the association between marital status and depression (4, 14, 18, 26, 37, 53) . Glioma patients who were married were as likely as unmarried patients to experience depression. This was the case regardless of whether depression was assessed preoperatively (4), postoperatively (37), during follow-up (14, 18, 26) , or after recurrence (53) . We found no studies that examined this
Two studies (4, 26) reported that past psychiatric history was associated with depression, and two studies (5, 14) reported that it was not. Direct comparison of positive and negative studies was difficult because they used different definitions of past psychiatric history (eg, any psychiatric illness, treatment for depression specifically, or previous suicide attempt). The association between past psychiatric history and depression was not specifically studied in patients with high-grade or low-grade glioma. Overall, past psychiatric history was not a clear risk factor for depression in patients with glioma.
Reduced physical function was associated with an increased likelihood of depression in five studies (4, 5, (20) (21) (22) , but not in others (13, 18, 24) . Physical function was measured with the Karnovsky Performance Scale (61) in four studies (4, 13, 21, 24) and with the Barthel Index (62), which provides a measure of disability, in two studies (5, 20) . The most consistent association was between disability and a higher HADS score in glioma patients during follow-up (5, 20) . There was no evidence specific for patients with low-grade glioma, who tend to have epilepsy rather than physical impairments. The balance of evidence suggested that functional impairment is associated with depression in patients with glioma.
Five studies showed an association between cognitive impairment and depression (5, 15, 20, 22, 36) . However, a specific pattern of impairment across cognitive domains was not apparent, perhaps because different tests were applied at different times and in different populations. Depression was associated with cognitive impairment in patients with low-grade glioma assessed before undergoing chemotherapy (36) , in patients with high-grade glioma assessed during follow-up (22) , and in patients with any glioma assessed postoperatively (15) and during follow-up (5, 20) . All studies that examined this relationship used continuous scale scores to measure depression, and all positive studies used formal neuropsychological screening tests. The only study that used the Mini-Mental State Examination to screen for cognitive impairment found no association (30) , perhaps because this test is relatively insensitive. The evidence suggested that when detailed neuropsychological testing is used, depression is associated with cognitive impairment in glioma.
Few eligible studies enrolled black, Asian, Hispanic, or Native American patients with glioma. In one study (21) , black patients with high-grade glioma were found to be at statistically significantly higher risk of depression (P = .001) compared with patients of other ethnicities. However, the number of black patients in that study was small (18 of 598 patients were black), increasing the risk of a type I error (ie, false-positive finding). One study that assessed high-grade glioma patients preoperatively (in which 337 of 1003 patients were nonwhite) (13) , and another study that assessed patients with any glioma during follow-up (in which 18 of 363 patients were nonwhite) (26) reported that race or ethnicity was not associated with depression. We found no evidence specific for patients with lowgrade glioma. Overall, there was no consistent evidence that race or ethnicity is a risk factor for depression in glioma.
The three studies (18, 23, 26) in which education level was measured provided conflicting results. Each study used a different depression outcome measure and a different definition of education level. The association between education level and depression in patients with low-grade glioma was not specifically studied. Overall, education level was not a clear risk factor for depression in glioma.
Tumor-Related Variables
Among studies that enrolled small numbers of patients with brain tumors of different histological types (eg, metastasis, pituitary tumor, or meningioma), patients with glioma appeared to have a risk of depression similar to that of other brain tumor patients. This was the case regardless of whether depression was measured as a continuous (18, 24, 25, 40) or a dichotomous (4, 49) outcome. In studies eligible for this review, different brain tumor histologies showed no particular association with depression.
In most studies (5, 13, 15, 18, 21, 24, 30, 39) , WHO tumor grade was not associated with depression. In one study (26) , patients with grade 1 tumors were found to have a statistically significantly lower frequency of depression compared with patients with higher-grade tumors. However, in that study, the threshold for diagnosing depression was low (a score of 6 or more on the PHQ-9 scale compared with the usual cutoff of 10 or more). Whether the association would have persisted using a higher threshold, with a greater severity of symptoms, is unclear. The lack of an association between tumor grade and depression in most studies should be interpreted with caution because of the general lack of statistical power in comparisons of tumor grade subgroups. In addition, the largest studies (13,21,30 ) examined the association between tumor grade and depression only in patients with high-grade glioma (ie, WHO grades III and IV). In most studies, the assessment of depression was either conducted around the time of neurosurgery (13, 15, 21, 39) or at a much later stage in the outpatient clinic (5, 18, 26) . It is perhaps in the intervening period (ie, 1-3 months after surgery) that tumor grade might be expected to mediate differences in mood, as patients adjust to their different prognoses and treatment courses. Most studies that examined the relationship between depression and tumor grade did not assess patients at this potentially important time. Currently, there is no evidence that WHO glioma grade is associated with depression.
Five studies (4, 13, 21, 24, 30) found no association between tumors in the frontal lobe and depression. However, one study (14) reported that frontal lobe tumor location was independently associated with clinical depression. Studies that examined this association are hard to compare directly because they used different methods of classifying tumor location. It was variously classified according to lobe (13, 14, 21, 24, 30) , more specifically according to intralobe region (15) , and less specifically according to anterior or posterior location in the brain (4, 36) . The most anatomically detailed study (15) , which divided the frontal lobe into three areas, reported a statistically significant association between tumors in the "ventral frontal" lobe and postoperative depression. Notably, in this study, depression levels of patients classified as having a tumor in the "lateral frontal" and "all frontal" areas actually improved relative to preoperative measurements. To date, no study has further examined the hypothesis that tumors in different regions of the frontal lobe may exhibit differential associations with depression. It remains possible that negative studies, whether of any glioma (4) or specifically of high-grade (13, 21, 24, 30) or low-grade (36) glioma, may have been insufficiently anatomically detailed to identify such an association. Currently, there is no consistent evidence that tumor location and depression are associated.
In seven studies (14, 15, (24) (25) (26) 30, 36) , hemispheric laterality of glioma was not associated with depression. One study (31) reported an association between left-sided tumors and depression in female patients. Studies that analyze the association between depression and hemispheric tumor laterality need particularly careful interpretation. They are potentially biased if, as was sometimes the case (15, 24, 31, 36) , patients with severe language difficulties are excluded. Such patients may have predominantly left-hemisphere tumors and may be more distressed because of their disability. Other studies examining this relationship (14, 25, 26, 30) did not specify whether severely dysphasic patients were excluded or not. Among the studies in this review, depression was not more likely to occur in patients with left-sided glioma.
Large tumors were associated with depression in two studies (15,21) but not in another study (24) . Neither study that reported a positive association clearly stated its criteria for considering a tumor "large." All three studies used different methods of diagnosing depression. The authors of one study (15) hypothesized that tumor size and depression may show a stronger association for tumors in certain anatomically critical locations. We found no studies that explored this hypothesis in more detail, however. There were no data for patients with low-grade glioma specifically. Tumor size is a possible risk factor for depression in glioma, but the current evidence is inconsistent.
Treatment-Related Factors
No study found an association between the extent of tumor resection and depression, regardless of whether depression was measured before (13, 38) or after (21, 30, 31, 40) surgery. The extent of resection was classified differently among the studies, with some comparing biopsy with any resection (21, 31, 40) and others additionally distinguishing between partial and total resection (13, 38) . The extent of tumor resection was not associated with depression among the studies in this review.
Treatment with radiotherapy was not associated with depression, whether assessed before (39) or after (18, 21, 30, 47) surgery and irrespective of tumor grade. However, no studies examined this association specifically in patients with low-grade glioma. Associations between depression and different radiotherapy schedules of varying radiation doses have not been studied in glioma. The long-term impact of any form of radiotherapy on depression is also largely unknown. Only one small study (47) recruited patients more than 1 year after diagnosis, and it found no association. It is possible that depression could be a longer-term complication of cranial irradiation. The evidence currently suggests that cranial radiotherapy is not associated with depression in glioma patients; however, potentially important long-term consequences of radiotherapy with respect to depression are not well understood.
Treatment with chemotherapy was not associated with depression either before (13) or after (18, 21, 24) surgery. Most studies that examined this association were conducted before temozolomide became the standard chemotherapy for glioblastoma multiforme. No studies examined the association between chemotherapy and depression in patients with low-grade glioma. There is no evidence that chemotherapy per se is associated with depression, but studies specific for patients treated with temozolomide are lacking.
Although corticosteroids have been specifically implicated in reviews (1,2) as a potential cause of depression in glioma, there was little evidence for such an association either in patients with glioma in general (31) or with high-grade glioma in particular (21, 24, 30) . One large longitudinal study of patients with high-grade glioma found a statistically significant univariate association between steroid prescription and depression at 6 months postoperatively. In this study, the frequency of depression was 71.4% among patients taking steroids vs 44.3% among those who were not prescribed steroids (P < .002) (21) . However, the analysis did not control for relevant confounding variables, including functional impairment. There were no data specific for patients with low-grade glioma. There is currently no consistent evidence that steroid use is associated with depression in glioma patients.
Few studies examined the association between the use of antiepileptic drugs and depression. Use of antiepileptic drugs was not associated with depression in the postoperative period in patients with high-grade (24, 30) or any grade (15) glioma. Associations between antiepileptic drug use and depression were not studied specifically in patients with low-grade glioma, despite the much higher prevalence of epilepsy in this subgroup (59) . This area deserves further study because antiepileptic drugs have been associated with the onset of depression in other patient groups (63) . Currently, however, there is no evidence that antiepileptic drugs are associated with depression in patients with glioma.
Outcome-Related Factors
Two longitudinal studies found that depression levels in glioma patients generally declined during the first 3 months after surgery (4, 31) . In one study (4) , depression levels continued to decrease statistically significantly over the first postoperative year in men (P = .047), but not in women. By contrast, other studies with 1 (25) to 6 (36) years of follow-up reported increasing levels of depression over time. The single study (36) with long-term follow-up data in low-grade glioma (albeit for only six of 57 patients) reported that depression scores increased statistically significantly 4-6 years after the baseline measurement (P < .02). The longitudinal course of depression cannot be determined from crosssectional studies. However, among cross-sectional studies, the length of time since glioma diagnosis consistently showed no association with overall levels of depression, regardless of whether sampling was perioperative (15) or during long-term follow-up (18, 23, 26) . Overall, longitudinal studies suggest that patients' depression levels do change over time, but the direction of change is inconsistent. It is possible that after a diagnosis of glioma, depression levels initially reduce in frequency and severity over several months, but increase thereafter. Longitudinal studies are needed to further clarify the time course of depression in glioma.
In a univariate analysis, physician-defined depression was associated with reduced survival in one large prospective study of patients with high-grade glioma (21) . Another large retrospective study found that depression was an independent predictor of reduced survival in patients with high-grade glioma (13) . Although the authors of the latter study controlled for several important confounders, they did not appear to control for radiotherapy. Higher levels of depression were associated with reduced 5-and 10-year survival in analyses of 16 patients with low-grade glioma that controlled for some, but not all, relevant variables (39, 41) . Depression may be associated with reduced survival in glioma patients, but existing research does not exclude a potential confounding effect of unmeasured variables. This important outcome could be studied further.
Seven studies (18, 22, 23, 28, 40, 51, 53) reported that depression was associated with reduced quality of life among glioma patients, and two studies (30, 54) reported that it was not. Another study observed that the association between depression and quality of life was influenced by functional status, cognitive impairment, or the patient's sex (4). There was not enough corroborative evidence to draw firm conclusions for patients with either low-grade or highgrade glioma specifically. However, in general, the balance of evidence suggests that depressed glioma patients have a reduced quality of life.
Few studies examined the association between depression and the frequency of medical complications among glioma patients. One group (21) reported that depression was statistically significantly associated with deep venous thrombosis, whereas other researchers (13) reported that it was not. Depression was also associated with epileptic seizures, systemic infections, and adverse drug reactions in the only study to measure these outcomes (21) . The same study found no association between depression and wound infections, contradicting a retrospective review which concluded that depression was independently associated with wound infection in patients with high-grade glioma who had received Gliadel (Eisai, Inc, Woodcliff Lake, NJ) (29) . The potential impact of depression on medical complication rates in patients with low-grade glioma, and in glioma patients as a whole, has not been examined. An association with any one complication was not independently confirmed by another study.
We found no data for patients with low-grade glioma regarding the association between depression and employment status even though these patients may often return to work after surgery. Two studies (4, 18) that used similar scales to assess depression in patients with any grade of glioma reached different conclusions. Patients in the positive study (18) were younger and in follow-up after primary treatment at the point of assessment for depression. By contrast, the study that reported no association (4) assessed depression before surgery. The patients in these two studies represent different clinical groups that cannot easily be compared. Another study (46) found that depression was independently associated with reduced work productivity among survivors of high-grade glioma. The bulk of the evidence suggests that postoperative depression may be associated with reduced likelihood of returning to work.
Associations Examined Once in Published Literature
Factors that were found to be independently associated with depression in glioma patients in a single study include anxious personality traits (25) and a family history of psychiatric illness (14) . Univariate associations were examined and found, in a single study, between depression and somatizing personality traits (36) , lower intelligence (15) , multifocal tumors (21) , and having a tumor recurrence (28) . A greater frequency of depression in the glioma patient was also associated with greater caregiver distress (48) . Variables that were not associated with depression in the single study to examine them included awareness of prognosis (5), previous medical illness (26) , and the rate of dropout from a longitudinal study (50) .
Treatment of Depression
Few observational studies examined the treatment of depression in glioma patients. Where reported, antidepressants were prescribed for 6.0%-16.8% of patients (24, 46) . In three studies (21, 26, 36) that reported both depression prevalence and antidepressant prescription frequency, antidepressants appeared to be underprescribed. For example, in one study (36) , 33% of the patients were depressed, but only 12% had been prescribed antidepressants. In another study (21) , 15% of the patients had been diagnosed with depression by their doctors, but only 7% were taking antidepressants. In another study (26) , 41% of the patients had symptoms of depression, but only 26% were taking "psychiatric medication." Concurrent antidepressant treatment was not associated with a reduced frequency of depression or improved quality of life in one uncontrolled longitudinal study of a selected sample of patients (21) . No observational study reported outcomes of psychological treatments for depression in patients with glioma.
Quality of Study Reporting
The quality of study reporting varied considerably compared with STROBE guidelines (33) . The likelihood of selection bias was often unclear because many authors did not report the total number of patients who had been approached to participate in their study (4, (19) (20) (21) 24, 26, 30, 31, 36, 37, (39) (40) (41) 43, 46, 48, 50, 52, 57) . It is likely that some patients who were asked to participate refused, given that only three of the 16 studies that reported this information achieved 100% recruitment (14, 55, 56) . Many studies did not formally state the exclusion criteria (5, 14, 20, 21, 30, 37, 46, 47, 52, 54, 55, 57) . Although some studies may have included all patients by default, many others excluded patients with severe cognitive impairment (15, 19, 25, 26, 36, 40, 43, 51, 53) and/or dysphasia (15, 16, (22) (23) (24) 31, 36, 38, 40, 43, 45) . Excluding patients tends to limit the generalizability of study findings; therefore, it is particularly important to describe exclusions in studies of glioma patients, who may have many disabilities.
No study reported results of sensitivity analyses, for example, results based on different depression scale cutoffs. Ninety-five percent confidence intervals on frequency estimates were generally not provided and, because the sample sizes were often small, were probably wide. Further uncertainty likely arises from the practical difficulty of sampling all glioma patients in a timely manner [eg, in one study (44) , only 75 of 92 patients were assessed for depression within 3 months of glioma diagnosis]. Most longitudinal studies reported having followed up patients at protocol-defined time points but did not state the actual range of time achieved around each point (4, 21, 25, (38) (39) (40) (41) 43) .
Among the eligible studies, elements of the statistical analyses were often unsatisfactory. Most of the larger studies [eg, (13, 15, 21, 26, 40) ] did not report that power calculations or correction for multiple statistical tests were performed. In some studies (14, 28, 29) , multiple regression analysis was used to provide confounder-adjusted estimates. Ordinarily this approach would be beneficial, but in an underpowered study, it could increase the risk of a false-positive result. Peduzzi et al. (64) estimated that each variable tested in a multivariable model requires a minimum of 10 case patients (ie, 10 depressed patients). Some studies (14, 29) appear to have conducted multiple regression analysis using a larger number of variables than was appropriate under this broad rule of thumb. The use of multiple regression analysis in another study was limited for precisely this reason (28) .
The STROBE guidelines were published in 2007, after many of the studies that were eligible for this review. Our main aim in highlighting shortfalls in the quality of study reporting is to identify areas that were commonly overlooked in previous studies and to help improve the design and reporting of future studies. It would be particularly useful for future observational reports of depression in glioma to clearly state the total numbers of patients who were eligible and approached, to record exclusion criteria, and to present estimates of precision (eg, 95% confidence intervals). Authors of future studies should conduct sensitivity analyses to examine the stability of their results. Finally, authors should be aware that very large sample sizes may be needed to control for the multiple confounding variables present in this population of patients.
Discussion
Most observational studies of depression in adults with glioma were small, cross-sectional, and/or retrospective. Among the instruments that were used to screen for depression, the BDI appeared to inflate depression frequency compared with clinical interview. The HADS may be a better choice as an initial screening instrument. Clinically diagnosable depression occurred in roughly 15% of glioma patients, and clinicians should anticipate this frequency of psychological morbidity among patients with glioma. Depression was consistently associated with functional impairment, cognitive dysfunction, and reduced quality of life. Depression was also associated with reduced survival; however, the studies that reported this association had methodological flaws. Evidence for other associations was contradictory or absent. Few studies conducted multivariable analyses. The quality of study reporting was variable, which limited comparability and generalizability of the findings.
These conclusions should be considered in light of the potential limitations of this review. There was a risk of selection bias in the included studies because we excluded non-English-language papers and studies that enrolled patients who were younger than 18 years. The search strategy was relatively insensitive for palliative care populations because we excluded studies in which glioma patients constituted only a small proportion of the total sample. Therefore, our results are probably less representative of the terminal phase of the illness. We also excluded studies that recruited patients with a primary brain tumor if the number of patients with glioma was not stated. Although we made this exclusion to improve the specificity of our results to glioma, we may have excluded some glioma-specific data as a result. We similarly restricted the focus of our review by excluding quality-of-life studies. Included studies, by their sampling strategy, were generally biased toward younger patients who had reasonably good cognitive and physical functioning. Our conclusions therefore apply more to these clinical groups. Despite considerable efforts, it was often difficult to compare results of different studies. Our findings represent our interpretation of the balance of the current evidence.
Many different methods of diagnosing depression were identified in this review. To our knowledge, no depression rating scale has been validated in patients with glioma. Studies that used the BDI and the PHQ-9 reported a clinically significantly higher prevalence of depression than those that used the HADS. The HADS is designed to minimize confounding from somatic symptoms of medical illness, such as changes in appetite and sleep (60) . We recognize that some caution is required in directly comparing results drawn from different patient samples. In addition, the PHQ-9 was used in only one study (26) and at a low and possibly nonspecific threshold. Nevertheless, existing data suggest that the HADS is the more accurate initial depression screening instrument in glioma, perhaps partly because it largely excludes somatic items. When it is impractical to use a clinical interview to diagnose depression in a glioma patient, we suggest using the depression subscale of the HADS. The HADS has been criticized for having poor receiver operating characteristics in palliative care populations (65) . It may also be difficult to use in patients with hemiparesis, hemianopia, hemisensory neglect, or dysphasia. However, it was the most widely used individual depression rating scale among the studies included in this review, and it identified suprathreshold levels of depressive symptoms with roughly the same frequency as clinical interview.
This review also illustrates the potential impact of depression on the lives of glioma patients. Positive associations between depression and reduced quality of life, functional and cognitive impairment, caregiver distress, and reduced likelihood of returning to work reinforce the importance of identifying and treating depression in adults with glioma. Although depression is associated with reduced survival in patients with systemic cancers (12) , an association between depression and survival in glioma is less clear in part because of the lack of studies and in part because of inadequate controlling for important prognostic variables. However, such an association cannot be excluded and may exist based on the available evidence. Detecting differences in survival in such a naturally aggressive disease as glioma may require a large sample size. Both of the studies that reported an association between depression and decreased survival in patients with high-grade glioma recruited more than 500 patients (13, 21) .
The absence of strong associations with other variables (including tumor location, histology, and extent of resection) implies that depression in glioma is primarily a psychologically mediated response to losses, including the loss of health. However, this review does not exclude the possibility that tumor-related factors play an indirect role in the etiology of glioma-associated depression, for several reasons. First, many associations have been studied too infrequently to draw firm conclusions. Second, existing studies are difficult to compare reliably. Third, lobe-based analysis of tumor location, in particular, is a crude measure. Neural circuits thought to be involved in mood regulation cross multiple anatomical boundaries (32) . A shift in emphasis toward the examination of the impact of brain tumors on functional neuroanatomical networks has been proposed (15) and deserves to be studied. It is important to recognize that the impact of tumor biology on the pathogenesis of depressive and the emotional response to glioma diagnosis remains largely unknown.
We hope that this review will educate clinicians about various aspects of depression in glioma. Awareness by clinicians that male patients, older patients, and those with low-grade glioma appear to have an equal risk of experiencing depression may improve screening and recognition rates. We suggest that whenever possible, authors of future observational studies of depression in glioma follow the STROBE guidelines when reporting their findings. Coupled with the peer review process, these measures may improve the quality of reporting and facilitate comparisons among studies. To this end, variables that may benefit from clear definition include marital status, past psychiatric history, physical function, cognitive function, race and ethnicity, tumor lobe, tumor histology, tumor size, extent of resection, radiotherapy, chemotherapy, steroids, epilepsy, quality of life, and medical complications. 
